Bial Discontinues Pariceract After Phase 2b ACTIVATE Trial Miss
PORTO, Portugal, June 9, 2026 Bial announced topline results from its Phase 2b ACTIVATE study evaluating BIA 28-6156 (pariceract)...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
PORTO, Portugal, June 9, 2026 Bial announced topline results from its Phase 2b ACTIVATE study evaluating BIA 28-6156 (pariceract)...
